Summary: Aetna, a CVS Health company, modified CPB 0671 governing enfuvirtide (Fuzeon) coverage, effective March 26, 2026. Here's what billing teams need to know before submitting claims under HCPCS code J1324.
This update to the Aetna enfuvirtide coverage policy clarifies the medical necessity criteria for both initial approval and continuation of therapy for HIV-1 infection. If your practice bills J1324 for enfuvirtide injections to Aetna commercial members, this policy directly affects your documentation requirements and claim submission workflow. The stakes are real — enfuvirtide is not a cheap drug, and a claim denial on J1324 without the right clinical documentation in the record is a significant revenue hit.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Enfuvirtide (Fuzeon) — CPB 0671 |
| Policy Code | CPB 0671 |
| Change Type | Modified |
| Effective Date | March 26, 2026 |
| Impact Level | Medium |
| Specialties Affected | Infectious Disease, HIV/AIDS Specialty Clinics, Internal Medicine, Pharmacy Billing |
| Key Action | Confirm that J1324 claims include documentation of viremia plus prior treatment failure or resistance before billing Aetna commercial plans |
Aetna Enfuvirtide Coverage Criteria and Medical Necessity Requirements 2026
The Aetna enfuvirtide coverage policy under CPB 0671 in the Aetna system sets two distinct pathways for initial medical necessity approval. Your billing team needs to know both.
Pathway 1: The member has viremia despite at least three months of therapy with at least one appropriate HIV treatment regimen. The documentation needs to show duration of prior therapy and ongoing detectable viral load.
Pathway 2: The member has viremia and documented resistance or intolerance to at least one appropriate HIV regimen. Here, resistance testing results or documented intolerance need to be in the chart before you bill J1324.
Both pathways require viremia as a baseline condition. You can't bill enfuvirtide billing under this policy for a virologically suppressed patient — full stop. If the chart doesn't reflect active viremia at the time of initiation, expect a claim denial.
The prior authorization question matters here. While CPB 0671 doesn't explicitly state prior auth is required in every case, Aetna commercial plans routinely apply utilization management to injectable HIV medications. Treat prior authorization as a practical requirement and pull the prior auth before dispensing or administering enfuvirtide. Don't wait until after administration to confirm coverage — that's how you get an unpayable claim.
For continuation of therapy, the criteria are more straightforward. Aetna considers ongoing enfuvirtide medically necessary when the member has had a positive or stable virologic response. "Positive or stable" gives you some room — a patient who hasn't achieved full suppression but is trending stable can still meet the bar. Document the virologic trend in your records and reference it explicitly in any continuation authorization requests.
Reimbursement under this policy flows through HCPCS code J1324, billed per 1 mg of enfuvirtide injected. Enfuvirtide is dosed at 90 mg twice daily, so the unit count per administration matters. Miscounting units on J1324 is one of the most common billing errors on this drug — double-check your charge capture against the actual dose administered.
Aetna Enfuvirtide Exclusions and Non-Covered Indications
Aetna considers all uses of enfuvirtide outside HIV-1 treatment — as described in the initial approval criteria above — to be experimental, investigational, or unproven. There are no other covered indications under CPB 0671.
This is a narrow policy by design. Enfuvirtide is a fusion inhibitor approved specifically for HIV-1. Any off-label use — for HIV-2, for prophylaxis, or for any indication not tied to active HIV-1 infection with documented treatment failure or resistance — will not pass Aetna's medical necessity review.
One thing to flag: ICD-10 code U07.1 (COVID-19) appears in the code table attached to this policy. That is almost certainly a data artifact, not a covered indication. Do not bill J1324 with a primary diagnosis of U07.1 and expect coverage. If your billing system auto-populates diagnosis codes from a code table, make sure that code is filtered out. Billing J1324 with U07.1 as the primary diagnosis will generate a claim denial and could raise audit flags.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HIV-1 infection with viremia after 3+ months of prior therapy | Covered | J1324, B20 | Document duration of prior therapy and current viremia |
| HIV-1 infection with viremia and documented resistance or intolerance to prior regimen | Covered | J1324, B20 | Resistance testing or intolerance documentation required in chart |
| Continuation of therapy with positive or stable virologic response | Covered | J1324, B20 | Document virologic trend at each reassessment |
| All other indications (off-label, HIV-2, prophylaxis, etc.) | Not Covered — Experimental/Investigational | — | No coverage under CPB 0671 for non-HIV-1 or non-failing-treatment use |
| COVID-19 (U07.1) | Not a covered indication | U07.1 | Code appears in policy data but is not a valid enfuvirtide indication — do not use as primary dx |
Aetna Enfuvirtide Billing Guidelines and Action Items 2026
These action items apply to any practice or billing team that submits J1324 claims to Aetna commercial plans.
| # | Action Item |
|---|---|
| 1 | Audit your active J1324 claims before March 26, 2026. Pull every open or pending Aetna claim for J1324 and confirm each one has documentation of viremia and either prior treatment duration or resistance/intolerance on file. Claims that don't have this documentation are denial risks under the updated CPB 0671. |
| 2 | Set B20 as the required primary diagnosis for all J1324 claims. The ICD-10 code for HIV disease (B20) is the correct primary diagnosis under this policy. Build a claim edit in your billing system that flags any J1324 claim submitted without B20 as the primary dx. This is a simple rule that prevents a predictable error. |
| 3 | Flag U07.1 as an invalid diagnosis for J1324 in your system. U07.1 (COVID-19) appears in the CPB 0671 code table but is not a covered indication for enfuvirtide. Add a hard stop in your charge capture or claim scrubber that blocks J1324 from being submitted with U07.1 as any diagnosis code. |
| 4 | Verify unit billing on J1324 matches the actual dose administered. Enfuvirtide is dosed at 90 mg twice daily. J1324 is billed per 1 mg. That means each administration should generate 90 units. If your system auto-populates units, confirm the configuration is correct for this drug specifically — J1324 unit errors are a frequent source of underbilling and overbilling on this code. |
| 5 | Treat prior authorization as mandatory for new starts, even if the plan doesn't explicitly require it. The billing guidelines under CPB 0671 don't state prior auth is required in every case, but Aetna commercial plans consistently apply utilization management to specialty injectables like enfuvirtide. Pull the prior auth before the first administration. Document the authorization number in your billing record. |
| 6 | For continuation requests, document virologic response explicitly. When submitting a continuation authorization, include the member's viral load trend — not just a single value. "Stable virologic response" is Aetna's threshold, and a trend line is far more persuasive than a single lab result. Your clinical team needs to know this is what the authorization reviewer is looking for. |
| 7 | If you're uncertain how this policy applies to your specific Aetna plan mix, talk to your compliance officer before March 26, 2026. CPB 0671 covers commercial medical plans. Aetna Medicare Advantage and Medicaid plans may have different criteria. Don't assume this policy applies uniformly across all Aetna products your practice bills. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Enfuvirtide Under CPB 0671
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1324 | HCPCS | Injection, enfuvirtide, 1 mg |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Notes |
|---|---|---|
| B20 | Human immunodeficiency virus [HIV] disease | Primary dx for covered enfuvirtide claims |
| U07.1 | COVID-19 | Listed in policy code table — NOT a covered indication for enfuvirtide; do not use as primary dx for J1324 |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.